Guggenheim Initiates Coverage On Aerovate Therapeutics With Buy Rating, Announces Price Target of $36
Guggenheim Initiates Coverage On Aerovate Therapeutics With Buy Rating, Announces Price Target of $36
古根海姆以買入評級開始對Aerovate Therapeutics進行報道,宣佈目標股價爲36美元
Guggenheim analyst Vamil Divan initiates coverage on Aerovate Therapeutics (NASDAQ:AVTE) with a Buy rating and announces Price Target of $36.
古根海姆分析師瓦米爾·迪萬開始對Aerovate Therapeutics(納斯達克股票代碼:AVTE)進行報道,評級爲買入,並宣佈目標股價爲36美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。